Called CanPathPro, the research consortium aims to combine omics data and systems biology tools into a single commercial platform for testing cancer hypotheses.
Snyder's new book, "Genomics and Personalized Medicine," serves as a primer for patients and doctors, touching on topics from tailored cancer therapy to wearable devices.
Though cancer experts noted many tests under MEDCAC review were developed to be predictive of treatment response, CMS maintained the meeting's focus on the prognostic context.
The HIV Treatment Response Prediction System averages the output of four trained random forest models to predict response to antiretroviral drugs based on viral load, CD4 counts, HIV genotypes, and records of antiretroviral drug treatments.
The patents add to others held by Myriad covering pancreatic cancer markers.
In Science this week: genetic target for urothelial bladder cancer treatment, and more.
At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.
Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.
Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.